Alluvi, previously BI 4744, offers a notable breakthrough in obesity treatment. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive efficacy in patient assessments, https://socials360.com/story12845506/alluvi-a-detailed-examination-into-the-medication-s-potential